| Acceptance rate | 46% |
|---|---|
| Time to first decision | 6 months* |
| Time to decision with review | 50 days* |
*Approximate number of days
**The days mentioned above are averages and do not indicate exact durations. The process may vary for each article.
ACTA Pharmaceutica Sciencia
2025 , Vol 63 , Num 1
Formulation and characterization of lercanidipine HCl nanoparticles as fast-dissolving sublingual film
1 Baghdad University, College of Pharmacy, Department of Pharmaceutics, Baghdad, IraqDOI : 10.23893/1307-2080.APS6303 Viewed : 84 - Downloaded : 39 Calcium channel blocker lercanidipine HCl treats hypertension and angina pectoris. It is a biopharmaceutical classification system (BCS) class II drug due to its poor water solubility. First-pass metabolism and low solubility reduce lercanidipine HCl oral bioavailability to 10%. This research aims to improve the dissolution rate of lercanidipine HCl by developing a nanosuspension and then transforming it into a sublingual fast-dissolving film with rapid disintegration, simple administration, and stability that will enhance patient adherence. The solvent-antisolvent precipitation technique produced lercanidipine HCl nanosuspension. Sublingual fast-dissolving films contain lercanidipine HCl nanoparticles produced by solvent casting. The dissolution rate increased significantly in nanosuspension. Film formulations using 50% polyvinyl alcohol and 30% glycerin produced excellent results. Formula F4 is optimal due to its 25-second disintegration and 99.8% in vitro drug release in 4 minutes. The study observed that lercanidipine HCl sublingual film offered an effective drug delivery system with improved disintegration and patient compliance. Keywords : lercanidipine HCl, nanoparticles, PVA, solvent casting, sublingual film